BEAM vs VRTX
BEAM and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $2.62B | $121.07B |
| P/E (TTM) | — | 28.3 |
| P/B | 2.25 | 6.25 |
| P/S | 18.8x | 10.1x |
| Revenue | $164.01M(TTM) | $12.22B(TTM) |
| Revenue growth (YoY) | 120.0% | 8.9% |
| Net income | -$65.98M(TTM) | $4.34B(TTM) |
| Earnings growth (YoY) | 78.8% | 838.1% |
| EPS, diluted | $-0.49(TTM) | $16.85(TTM) |
| EBIT margin | -274.6% | 34.8% |
| ROE | -6.9% | 20.4% |
| ROIC | -39.3% | 25.4% |
| 1y total return | +29.3% | +4.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BEAM vs VRTX
| Metric | BEAM | VRTX |
|---|---|---|
| End value | $13.6K | $20.0K |
| Total return | +36.1% | +99.5% |
| CAGR | +4.9% | +11.3% |
| Volatility | 80.1% | 32.0% |
| Sharpe | 0.41 | 0.38 |
| Sortino | 0.62 | 0.51 |
| Max drawdown | -89.1% | -41.6% |
Based on 1629 common trading days, 2020-02-06 → 2026-07-31 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)